Figure 3.

Cooperation of Akt and MEK signalling in TNBC proliferation. (A) Western blot analysis after inhibition by MEK inhibitors (selumetinib and PD184352) and Akt inhibitors (ipatasertib and MK-2206). Cells were treated with inhibitors (1 µM) for 24 hours. Data are representative of two independent experiments. (B) Combined inhibition by increasing concentrations of selumetinib or ipatasertib (0.00316–10 µM), together with a fixed concentration of ipatasertib or selumetinib (1 µM), respectively. Data are expressed as means ± SD from three independent experiments. Full-length uncropped blots, including internal controls to compare across blots, are shown in Supplementary Fig. S4.